After seven months of continuing resolutions, Congress voted to pass a $1.1 trillion spending bill covering the remainder of the fiscal year 2017—approving a $2 billion increase for NIH.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
